Nxera Pharma Secures Japanese Approval for QUVIVIQ™ to Treat Insomnia Based on Positive Phase 3 Trial Results

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...

September 24, 2024 | Tuesday | News
Novo Nordisk’s Wegovy® Receives Positive Opinion from EMA for Label Update Reflecting Reduced Heart Failure Symptoms

Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opin...

September 20, 2024 | Friday | News
Astellas Launches DIGITIVA™, a New Digital Health Solution for Heart Failure Management

New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -...

September 19, 2024 | Thursday | News
Thermo Fisher's PPD Clinical Research Expands to GoCo Health Innovation City in Sweden

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...

September 19, 2024 | Thursday | News
Vidac Pharma Secures Broad U.S. Patent for Pioneering Cancer Treatment Mode of Action

Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments,  announces that the U...

September 19, 2024 | Thursday | News
Roche's Xofluza Shows Single-Dose Can Reduce Influenza Transmission in Landmark Global Study

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members This is the f...

September 19, 2024 | Thursday | News
BeiGene Secures Israeli Ministry of Health Approval for TEVIMBRA® in Treating Esophageal Squamous Cell Carcinoma

BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...

September 18, 2024 | Wednesday | News
Immutep Presents Promising Phase IIb Trial Results of Efti and KEYTRUDA® at ESMO 2024

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...

September 17, 2024 | Tuesday | News
Shuttle Pharmaceuticals Expands Phase 2 Glioblastoma Trial with Two Additional Sites

Shuttle Pharmaceuticals Holdings, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients tr...

September 17, 2024 | Tuesday | News
Genmab’s Rina-S Shows Promising 50% Response Rate in Heavily Pretreated Ovarian Cancer Patients

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion coho...

September 16, 2024 | Monday | News
FDA Approves Roche’s OCREVUS ZUNOVO™ for Subcutaneous MS Treatment, Expanding Access for Patients

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's off...

September 16, 2024 | Monday | News
PolTREG Secures Chinese Patent for Intrathecal Administration of MS Therapy, Set to Launch Phase 2 Trials

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal...

September 16, 2024 | Monday | News
Oneness Biotech and Microbio's Pan-COVID Drug SNS812 Achieves Key Phase 2 Trial Success, Showing Broad-Spectrum Efficacy

Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical significance wit...

September 11, 2024 | Wednesday | News
Vasa Therapeutics' Novel Heart Failure Treatment VS-041 Reaches Key Clinical Advancement with First Dosing in Human Trials

VS-041, a novel and potentially life-saving  treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology  comp...

September 11, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close